HighTower Advisors’s Dare Bioscience DARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-11,692
Closed -$24.6K 3733
2025
Q3
$24.6K Buy
+11,692
New +$26.4K ﹤0.01% 3661
2024
Q2
Sell
-900
Closed -$5K 3737
2024
Q1
$5K Sell
900
-2,992
-77% -$14.7K ﹤0.01% 3440
2023
Q4
$14K Buy
3,892
+3,000
+336% +$13.7K ﹤0.01% 3418
2023
Q3
$5K Hold
892
﹤0.01% 3425
2023
Q2
$10K Sell
892
-500
-36% -$5.94K ﹤0.01% 3304
2023
Q1
$17K Sell
1,392
-333
-19% -$4.42K ﹤0.01% 3160
2022
Q4
$17K Sell
1,725
-445
-21% -$4.97K ﹤0.01% 3141
2022
Q3
$26K Sell
2,170
-3,000
-58% -$41.2K ﹤0.01% 2949
2022
Q2
$76K Buy
5,170
+2,667
+107% +$40.1K ﹤0.01% 2846
2022
Q1
$45K Buy
2,503
+614
+33% +$11.6K ﹤0.01% 3084
2021
Q4
$45K Buy
1,889
+53
+3% +$1.09K ﹤0.01% 3034
2021
Q3
$36K Sell
1,836
-667
-27% -$13.1K ﹤0.01% 2965
2021
Q2
$57K Buy
2,503
+1,167
+87% +$19.9K ﹤0.01% 2877
2021
Q1
$27K Sell
1,336
-1,334
-50% -$32.5K ﹤0.01% 2881
2020
Q4
$42K Buy
2,670
+667
+33% +$9.35K ﹤0.01% 2426
2020
Q3
$24K Sell
2,003
-167
-8% -$2.23K ﹤0.01% 2360
2020
Q2
$26K Buy
2,170
+834
+62% +$10.2K ﹤0.01% 2238
2020
Q1
$14K Buy
+1,336
New +$18K ﹤0.01% 2101

Other funds holding DARE

HighTower Advisors's DARE Position: Q4 2025 in Review

HighTower Advisors sold out of Dare Bioscience (DARE) in Q4 2025, closing a stake of 11,692 shares — an estimated $24.6K sold.

HighTower Advisors first reported a position in DARE in Q1 2020 and held it in 18 quarters. The position peaked at $76K in Q2 2022. 27 funds tracked by Wall St. Rank hold DARE as of Q4 2025.

  • HighTower Advisors reported no remaining Dare Bioscience position as of Q4 2025 after selling out during the quarter.
  • HighTower Advisors sold 11,692 Dare Bioscience shares in Q4 2025, an estimated $24.6K.
  • HighTower Advisors first reported a position in Dare Bioscience in Q1 2020 and held it in 18 quarters.
  • HighTower Advisors's Dare Bioscience position peaked at $76K in Q2 2022.
  • 27 funds tracked by Wall St. Rank held Dare Bioscience as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.